Phase 2 Study of CD70-Targeted ImmunoPETCT Imaging for Diagnosing and Monitoring Renal Cancer, Lymphoma, and Nasopharyngeal Carcinoma

What this Trial Is About

Researchers are evaluating the use of CD70-targeted immuno-positron emission tomographycomputed tomography immunoPETCT imaging to diagnose several types of malignant cancers, including renal cell carcinoma especially clear cell renal cell carcinoma, lymphoma, and nasopharyngeal carcinoma NPC. This phase 2 study aims to assess how well these imaging tracers work compared to conventional imaging methods and how they might influence clinical decisions. The trial is sponsored by RenJi Hospital and focuses on both confirmed and suspected cases of these cancers. Participants will receive an injection of one of several radioactive tracers targeting CD70, including 18FF-RESCA-RCCB6, 18FF-RESCA-R8B4, 68GaGa-NOTA-R8B4, 18FF-RESCA-RD06, or 68GaGa-NOTA-RD06. After injection, patients will undergo whole-body immunoPETCT scans 1 to 2 hours later to capture images of tumors and normal tissues. The uptake of these tracers will be measured visually and quantitatively to evaluate diagnostic accuracy. Patients may also be followed for routine surveillance and to evaluate treatment response after the initial imaging. During the study, researchers will analyze the patterns of tracer uptake in tumors and compare them to conventional imaging results. They will use measures like sensitivity, specificity, positive and negative predictive values, and accuracy to assess the imagings diagnostic value. The impact of the imaging on clinical decision-making will also be evaluated over 3 to 6 months after tracer injection. Participants will be monitored for safety throughout the process, with the total study duration depending on follow-up assessments.

CD70-targeted immunoPET Imaging of Malignant Cancers